Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jul 1:6:44.
doi: 10.1186/1756-8722-6-44.

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Ningjing Lin, Yuqin Song, Wen Zheng, Meifeng Tu, Yan Xie, Xiaopei Wang, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Weiping Liu, Jun Zhu
Clinical Trial

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Ningjing Lin et al. J Hematol Oncol. .

Abstract

Purpose: To explore the efficacy and safety of L-asparaginase in newly-diagnosed extranodal nature killer (NK)/T -cell lymphoma (ENKTL), we conducted a prospective phase II study of L-asparaginase, cyclophosphamide, vincristine, doxorubicin and dexamethasone (CHOP-L) regimen in combination with radiotherapy.

Patients and methods: Patients with newly diagnosed ENKTL and an ECOG performance status of 0 to 2 were eligible for enrollment. Treatment included 6-8 cycles of CHOP-L (cyclophosphamide, 750 mg/m(2) day 1; vincristine, 1.4 mg/m(2) day 1 (maximal dose 2 mg), doxorubicin 50 mg/m(2) day 1; dexamethasone 10 mg days 1-8; L-asparaginase 6000 u/m(2) days 2-8). Radiotherapy was scheduled after 4-6 cycles of CHOP-L regimen, depending on stage and primary anatomic site. The primary endpoint was complete response (CR) rate.

Results: A total of 38 eligible patients were enrolled. The median age was 40.5 years (range, 15 to 71 years). Their clinical characteristics were male to female ratio, 24:14; Ann Arbor stage I, 20; II, 11; III, 3; IV, 4. CR and overall response rates were 81.6% (95% CI, 69.3% to 93.9%) and 84.2%, respectively. With a median follow-up of 25 months, the 2-year overall survival, progression-free survival and disease-free survival rates were 80.1% (95%CI, 73.3% to 86.9%), 81% (95%CI, 74.5% to 87.5%) and 93.6% (95%CI, 89.3% to 97.9%), respectively. The major adverse events were myelosuppression, liver dysfunction, and digestive tract toxicities. Grade 3 to 4 leukopenia and neutropenia were 76.3% and 84.2%, respectively. No treatment-related death was observed.

Conclusion: CHOP-L chemotherapy in combination with radiotherapy is a safe and highly effective treatment for newly diagnosed ENKTL.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of treatment scheme and outcomes.
Figure 2
Figure 2
The survival curves of 38 newly-diagnosed extranodal NK/T –cell lymphoma patients after CHOP-L plus radiation. (A) Overall survival, (B) Progression- free survival, (C) Disease- free survival.
See this image and copyright information in PMC

References

    1. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139(4):532–544. doi: 10.1111/j.1365-2141.2007.06835.x. - DOI - PubMed
    1. Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26(2):66–72. doi: 10.1002/hon.847. - DOI - PubMed
    1. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C. et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–434. doi: 10.1309/AJCP7YLTQPUSDQ5C. - DOI - PubMed
    1. Jain S, Zain J, O'Connor O. Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol. 2012;5(1):24. doi: 10.1186/1756-8722-5-24. - DOI - PMC - PubMed
    1. Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, Sng I, Tan LH, Ang MK, Ngeow J. et al. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol. 2008;80(1):55–60. - PubMed

Publication types

MeSH terms